Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:DRNANASDAQ:TBPHNASDAQ:YMABNASDAQ:ZGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.83-18.3%$1.62$0.49▼$2.48$383.15M0.784.19 million shs60.94 million shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/ATBPHTheravance Biopharma$8.97-0.4%$9.01$8.21▼$12.03$432.09M0.36369,312 shs401,710 shsYMABY-mAbs Therapeutics$16.26-1.5%$14.72$3.13▼$20.90$711.86M0.75413,353 shs270,332 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+12.00%+15.46%+48.34%+75.00%+273.77%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TBPHTheravance Biopharma+2.15%0.00%-2.38%-20.34%-14.84%YMABY-mAbs Therapeutics+5.10%+6.52%0.00%+123.27%+430.55%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1582 of 5 stars3.53.00.04.03.00.80.6DRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATBPHTheravance Biopharma1.9096 of 5 stars3.51.00.00.02.42.50.6YMABY-mAbs Therapeutics0.762 of 5 stars1.12.00.00.02.84.20.6ZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00173.22% UpsideDRNADicerna PharmaceuticalsN/AN/AN/AN/ATBPHTheravance Biopharma3.00Buy$20.00122.97% UpsideYMABY-mAbs Therapeutics2.29Hold$16.571.92% UpsideZGNXZogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest AKBA, DRNA, TBPH, ZGNX, and YMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/4/2024YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/4/2024YMABY-mAbs TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.002/20/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $21.002/12/2024YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $18.001/8/2024TBPHTheravance BiopharmaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.97N/AN/A($0.16) per share-11.44DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77TBPHTheravance Biopharma$57.42M7.52N/AN/A$4.28 per share2.10YMABY-mAbs Therapeutics$84.82M8.39N/AN/A$2.32 per share7.01ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/ATBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)ZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest AKBA, DRNA, TBPH, ZGNX, and YMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AAKBAAkebia TherapeuticsN/A-$0.04-$0.04N/AN/AN/A3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03DRNADicerna PharmaceuticalsN/A2.462.46TBPHTheravance BiopharmaN/A5.395.39YMABY-mAbs TherapeuticsN/A5.525.27ZGNXZogenix0.883.634.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%DRNADicerna Pharmaceuticals78.91%TBPHTheravance Biopharma99.10%YMABY-mAbs Therapeutics70.85%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%DRNADicerna Pharmaceuticals10.20%TBPHTheravance Biopharma5.30%YMABY-mAbs Therapeutics21.50%ZGNXZogenix4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics204209.37 million201.33 millionOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableTBPHTheravance Biopharma35948.17 million45.61 millionOptionableYMABY-mAbs Therapeutics10043.78 million34.37 millionOptionableZGNXZogenix21856.23 million53.92 millionOptionableAKBA, DRNA, TBPH, ZGNX, and YMAB HeadlinesSourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMOrally Inhaled Dihydroergotaminemedscape.com - February 13 at 4:11 PMMRI in Headachemedscape.com - August 25 at 10:47 PMKratom: What We Knowmedscape.com - August 13 at 5:03 PMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journalnews.google.com - May 10 at 11:58 PMGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRnews.google.com - May 4 at 4:03 PMNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan Newsnews.google.com - April 28 at 12:42 PMThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headachemedscape.com - April 25 at 2:50 PMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan Newsnews.google.com - April 24 at 9:21 AMAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journalnews.google.com - April 24 at 9:21 AMDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journalnews.google.com - April 20 at 12:29 AMForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comnews.google.com - April 19 at 7:28 PMDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome Newsnews.google.com - April 18 at 3:52 PMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journalnews.google.com - April 17 at 7:30 PMSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journalnews.google.com - April 17 at 7:30 PMEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journalnews.google.com - April 17 at 9:27 AMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswirenews.google.com - April 17 at 9:27 AMLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRnews.google.com - April 14 at 8:40 AMNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journalnews.google.com - April 13 at 5:40 PMNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRnews.google.com - April 12 at 1:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.ZogenixNASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.